Why the study?
The predictive value of reticulated platelets regarding adverse events in patients with acute coronary syndrome treated with prasugrel or ticagrelor was not fully understood.
Does immature platelet fraction predict death, myocardial infarction, or stroke at 1 year in patients with acute coronary syndrome treated with prasugrel or ticagrelor?
Does immature platelet fraction predict death, myocardial infarction, or stroke at 1 year in patients with acute coronary syndrome treated with prasugrel or ticagrelor?
Answers are grounded in this paper and cite their sources.
Immature platelet fraction is a promising biomarker for predicting adverse cardiovascular events in patients with acute coronary syndrome treated with potent P2Y12 inhibitors.
BACKGROUND: receptor inhibitors is not fully understood. We aimed to prospectively evaluate reticulated platelets as a predictor of the primary end point of the ISAR-REACT 5 trial consisting of death, myocardial infarction, or stroke at 1 year in patients with acute coronary syndrome randomized to prasugrel or ticagrelor. METHODS: group included patients with IPF≤median. Platelet aggregation was assessed using the Multiplate Analyzer and was correlated to IPF. CONCLUSIONS: Independently from drug treatment, IPF was associated with the primary end point and therefore is a promising biomarker for the prediction of adverse cardiovascular events in patients with acute coronary syndrome treated with prasugrel or ticagrelor. REGISTRATION: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01944800.
No takes yet. Share an insight, caveat, or question.
Bongiovanni et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: